stockmarketproxy
/
MIRMNasdaq SEC EDGAR

Mirum Pharmaceuticals, Inc.

Pharmaceutical Preparations·FOSTER CITY, CA·FY end 12/31·CIK 1759425
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$521.3M$336.9M$186.4M$77.1M$19.1M
Gross Profit——————
Operating Income-$22.1M-$87.6M-$109.2M-$131.2M-$173.4M
Net Income-$23.4M-$87.9M-$163.4M-$135.7M-$84.0M
Operating CF$55.8M$10.3M-$70.9M-$120.1M-$132.8M
Capex$954.0K$993.0K$109.0K$278.0K$24.0K
Free Cash Flow$54.9M$9.3M-$71.1M-$120.4M-$132.8M
Buybacks——————
Dividends——————
Gross Margin——————
Operating Margin-4.2%-26.0%-58.6%-170.3%-906.1%
Net Margin-4.5%-26.1%-87.7%-176.0%-438.9%
FCF Margin10.5%2.8%-38.1%-156.3%-693.8%
R&D / Revenue——————
Effective Tax-9.0%-1.2%-0.6%4.5%-0.0%
Debt / Equity——————
Buybacks / FCF——————

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
MIRM
24:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
MIRM
$10M
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
MIRM
-4.5%
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%